About this trial
Adult subjects with mild to moderate and moderate ED who meet the study eligibility criteria will be enrolled in the study. The enrolled subjects will be randomized by a 1:1 ratio to receive the Active or Sham VERTICA® treatment. Baseline assessments will include collection of demographic data, medical history, concomitant medications and baseline clinical examinations. The initial treatment session will be performed in a clinical setting simulating home use to determine proper device use and to evaluate device tolerability, followed by continued home use of the device for a total of 6 months. Patients will be instructed to attempt sexual activity periodically over the course of the study. Every time a sexual intercourse is attempted, the patient will be requested to complete an event log using validated assessments. Patients will present for monthly follow-up visits, during which safety will be evaluated and additional efficacy assessments will be performed.
Eligibility criteria
Qualifiers
Adult, heterosexual, males between 22 and 85 years of age
Subjects diagnosed with organic ED for at least 3 months, according to the American Urology Association (AUA) Guideline Statement 1 (as described in Section 8.1.1 of the study protocol).
Subjects with an IIEF-EF score between 11-21
Steady relationship for at least 3 months
Disqualifiers
Castrate and late onset hypogonadism
History of Priapism or Peyronie's Disease
Surgery or radiotherapy of the pelvic region
Anatomic penile deformations or penile prosthesis
Trial design
Treatments tested in this trial
- VERTICA Active device
- VERTICA Sham device